Refine
Has Fulltext
- no (78)
Year of publication
Document Type
- Article (78) (remove)
Is part of the Bibliography
- yes (78)
Keywords
- Vitamin A (5)
- retinol-binding protein 4 (4)
- HPLC (3)
- retinol (3)
- Biomarker (2)
- Dogs (2)
- RBP4 (2)
- Retinol (2)
- TTR (2)
- carotenoids (2)
- dog (2)
- iCheck (2)
- proteinuria (2)
- vitamin A (2)
- 3,4-didehydroretinol (1)
- Albumin (1)
- Antioxidant capacity (1)
- Asian subjects (1)
- Bioavailability (1)
- Birds of prey (1)
- Blood (1)
- Body composition (1)
- C-reactive protein (1)
- Catechin (1)
- Cattle (1)
- Cow-side assay (1)
- Curcumin (1)
- DPP-4 inhibitor (1)
- Diabetic nephropathy (1)
- Distal tubules (1)
- Dog growth (1)
- Donors (1)
- ER-stress (1)
- Emulsion (1)
- Energy intake (1)
- Equine metabolic syndrome (1)
- Equines (1)
- Euthyroid (1)
- First trimester (1)
- Horse (1)
- Hund (1)
- Inflammation (1)
- Intestinal absorption (1)
- Kalzium (1)
- Linagliptin (1)
- Low birth weight (1)
- Lutein ester (1)
- Marker (1)
- Mass spectrometry (1)
- Method comparison (1)
- Neutral lipids (1)
- New World camelids (1)
- Phospholipids (1)
- PlGF (1)
- Plasma concentration (1)
- Polyphenols (1)
- Polyurie/ Polydipsie (1)
- Post-translational modifications (1)
- Pregnancy (1)
- Preterm infant (1)
- Proteinuria (1)
- Proteome (1)
- Puppies (1)
- Relative dose response test (1)
- Renin-angiotensin system (1)
- Retinol-binding protein (1)
- Retinyl esters (1)
- Schimmelpilzinfektion (1)
- Small for gestational age (1)
- Species differences (1)
- Stability (1)
- T4 (1)
- Tagetes (1)
- Thin layer chromatography (1)
- Tocotrienols (1)
- Urine excretion (1)
- Very low birth weight infant (1)
- Vitamin A supplementation (1)
- Whey protein (1)
- alpha-Tocopherol (1)
- alpha-tocopherol (1)
- bioavailability (1)
- biomarker (1)
- birds of prey (1)
- body weight gain (1)
- calcium (1)
- canine osteoarthritis (1)
- carotenoid (1)
- chimpanzee (1)
- diet (1)
- dogs (1)
- egg yolk (1)
- equine (1)
- extra-cellular matrix (1)
- first trimester (1)
- gestational diabetes mellitus (GDM) (1)
- glomerular filtration rate (1)
- glucose metabolism (1)
- haemodialysis (1)
- hypertension (1)
- hypothyroid (1)
- inflammation (1)
- insulin (1)
- insulin resistance (1)
- kidney (1)
- kidney dysfunction (1)
- kidney transplantation (1)
- laminitis (1)
- large for gestational age fetus (LGA) (1)
- liver (1)
- lower nephron (1)
- lutein (1)
- method comparison (1)
- mortality (1)
- mould fungus (1)
- mouse (1)
- nutritional supplements (1)
- orangutan (1)
- plasma (1)
- polyuria/polydipsia (1)
- protein microheterogeneity (1)
- proteomix analysis (1)
- renal disease (1)
- renal function (1)
- retinoid-binding protein (1)
- retinol (ROH) (1)
- retinol-binding protein (1)
- retinyl esters (1)
- sFlt-1 (1)
- serum retinol binding protein (RBP4) (1)
- spectrophotometry (1)
- sudden death (1)
- synovial fluid (1)
- thyroid-stimulating hormone (1)
- thyroxine-binding (1)
- tocopherol (1)
- transthyretin (1)
- transthyretin (TTR) (1)
- type 2 diabetes (1)
- type 2 diabetes mellitus (1)
- urine (1)
- vitamin A deficiency (1)
- vitamins (1)
- yolk (1)
Institute
Background: The need for an improved treatment for diabetic nephropathy is greatest in patients who do not adequately respond to angiotensin II receptor blockers (ARBs). This study investigated the effect of the novel dipeptidyl peptidase-4 inhibitor linagliptin alone and in combination with the ARB telmisartan on the progression of diabetic nephropathy in diabetic endothelial nitric oxide synthase (eNOS) knockout mice. Methods: Sixty male eNOS knockout C57BL/6J mice were divided into four groups after receiving intraperitoneal high-dose streptozotocin: telmisartan (1 mg/kg), linagliptin (3 mg/kg), linagliptin + telmisartan (3 mg/kg + 1 mg/kg) and vehicle. Fourteen mice were used as non-diabetic controls. Results: After 12 weeks, urine and blood were obtained and blood pressure measured. Glucose concentrations were increased and similar in all diabetic groups. Telmisartan alone reduced systolic blood pressure by 5.9 mmHg versus diabetic controls (111.2 +/- 2.3 mmHg vs 117.1 +/- 2.2 mmHg; mean +/- SEM; P = 0.071). Combined treatment significantly reduced albuminuria compared with diabetic controls (71.7 +/- 15.3 mu g/24 h vs 170.8 +/- 34.2 mu g/24 h; P = 0.017), whereas the effects of single treatment with either telmisartan (97.8 +/- 26.4 mu g/24 h) or linagliptin (120.8 +/- 37.7 mu g/24 h) were not statistically significant. DPP-4 inhibition, alone and in combination, led to significantly lower plasma osteopontin levels compared with telmisartan alone. Histological analysis revealed reduced glomerulosclerosis after Linagliptin alone and in combination with telmisartan in comparison to non treated diabetic animals (p < 0.01 and p < 0.05). Kidney malonaldehyde immune-reactivity, a marker of oxidative stress, was significantly lower in animals treated with linagliptin. Conclusions: DPP-4 inhibition on top of ARB treatment significantly reduced urinary albumin excretion and oxidative stress in diabetic eNOS knockout mice. Linagliptin on top of an angiotensin II receptor blocker may offer a new therapeutic approach for patients with diabetic nephropathy.